Clinically, he treats adult and pediatric primary CNS tumors, and he is a member of the Yale radiosurgery team, with expertise in treating brain metastases and benign tumors such as arteriovenous malformations. Dr. Bindra received his undergraduate degree in Molecular Biophysics and Biochemistry from Yale University, and both his MD and PhD from the Yale School of Medicine. He completed his medical internship, radiation oncology residency, and post-doctoral research studies at the Memorial Sloan-Kettering Cancer Center. Dr. Bindra is the study co-chair of PNOC 017 and his group led a team of four major laboratories at Yale, which reported the stunning discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to PARP inhibitors.